Amgen Inc.'s Neupogen granulocyte colony stimulating factorhas received marketing approval in Germany. Neupogenstimulates the production in bone marrow of white blood cellsin patients receiving chemotherapy for certain cancers. Italready has marketing approval in five other Europeancountries and the United States. Neupogen will be sold inGermany by affiliates of both Amgen and Roche Holding AG.Stock of Thousand Oaks, Calif.-based Amgen (NASDAQ:AMGN)closed at $144.75, up $4, on Monday.
(c) 1997 American Health Consultants. All rights reserved.